Harmony Biosciences Holdings Inc. (HRMY) News

Harmony Biosciences Holdings Inc. (HRMY): $52.44

1.67 (+3.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HRMY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 403

in industry

Filter HRMY News Items

HRMY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HRMY News Highlights

  • For HRMY, its 30 day story count is now at 4.
  • Over the past 10 days, the trend for HRMY's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about HRMY are BLI, DRUG and RARE.

Latest HRMY News From Around the Web

Below are the latest news stories about Harmony Biosciences Holdings Inc that investors may wish to consider to help them evaluate HRMY as an investment opportunity.

Berkeley Lights, Inc. (BLI) Reports Q4 Loss, Tops Revenue Estimates

Berkeley Lights, Inc. (BLI) delivered earnings and revenue surprises of -4% and 5.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

3 Desirable Drug Stocks With Very Promising Pipelines

Drug makers with superb pipelines are likely to deliver great returns for long-term investors.

Larry Ramer on InvestorPlace | February 16, 2022

Read This Before Judging Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) ROE

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Yahoo | February 16, 2022

Harmony Biosciences Announces Date of Fourth Quarter and Full Year 2021 Financial Results

Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's fourth quarter and full year 2021 financial results on Monday, February 28, 2022. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.

Yahoo | February 14, 2022

When To Sell A Stock: This IBD 50 Pharma Stock Plummeted — Here's How To Avoid Major Losses

On Jan. 5, Harmony shares triggered an important sell rule upon entering the 7%-8% sell zone.

Yahoo | January 24, 2022

Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference

Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C. Jacobs will present a company update and host investor meetings at the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Yahoo | January 5, 2022

Datadog, Applied Materials Lead Five Stocks Near Buy Points For The New Year

Your stocks to watch for the week ahead are Datadog, Endava, Harmony Biosciences, Applied Materials and Danaher. AMAT stock and Danaher are on SwingTrader. Shares of Datadog are in a consolidation with a 186.38 handle buy point.

Yahoo | January 1, 2022

Analysts Expect Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Will Post Earnings of $0.34 Per Share

Equities research analysts expect Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) to announce earnings per share of $0.34 for the current quarter, Zacks reports. Four analysts have made estimates for Harmony Biosciences’ earnings, with the highest EPS estimate coming in at $0.42 and the lowest estimate coming in at $0.27. Harmony Biosciences reported earnings per share of […]

Transcript Daily | December 23, 2021

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Short Interest Update

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) was the recipient of a large increase in short interest in November. As of November 30th, there was short interest totalling 3,220,000 shares, an increase of 22.0% from the November 15th total of 2,640,000 shares. Currently, 12.9% of the companys stock are short sold. Based on an average daily volume []

Dakota Financial News | December 19, 2021

Harmony Biosciences to be Added to the Nasdaq Biotech Index

Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NBI). Harmony's addition to the NBI will become effective prior to market open on Monday, December 20, 2021.

Yahoo | December 17, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4312 seconds.